CN112773765A - 治疗普拉德-威利综合征的方法 - Google Patents

治疗普拉德-威利综合征的方法 Download PDF

Info

Publication number: CN112773765A
Authority: CN; China
Prior art keywords: carbetocin; day; substituted; pharmaceutically acceptable; acceptable salt
Prior art date: 2014-09-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN202110278199.4A

Other languages

English (en)

Chinese (zh)

Inventor

帕斯卡尔·丹格拉斯

迈克尔·雷迪

保罗·考纳尔

苏达考迪·阿拉加萨米

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Firelink

Ferring BV

Original Assignee

Firelink

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-19

Filing date

2015-09-14

Publication date

2021-05-11

2015-09-14 Application filed by Firelink filed Critical Firelink

2021-05-11 Publication of CN112773765A publication Critical patent/CN112773765A/zh

Status Pending legal-status Critical Current

Links

201000010769 Prader-Willi syndrome Diseases 0.000 title abstract description 39
238000000034 method Methods 0.000 title abstract description 17
150000003839 salts Chemical class 0.000 claims abstract description 20
NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 claims description 33
108700021293 carbetocin Proteins 0.000 claims description 32
229960001118 carbetocin Drugs 0.000 claims description 32
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
239000007922 nasal spray Substances 0.000 claims description 18
229940097496 nasal spray Drugs 0.000 claims description 17
239000007921 spray Substances 0.000 claims description 13
239000007864 aqueous solution Substances 0.000 claims description 9
239000011780 sodium chloride Substances 0.000 claims description 9
229940122381 Oxytocin receptor agonist Drugs 0.000 abstract description 24
239000000203 mixture Substances 0.000 abstract description 23
150000001875 compounds Chemical class 0.000 description 21
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 17
125000000217 alkyl group Chemical group 0.000 description 14
-1 amino substituted phenylalanine Chemical class 0.000 description 14
206010020710 Hyperphagia Diseases 0.000 description 13
125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
101500028587 Homo sapiens Oxytocin Proteins 0.000 description 12
235000008729 phenylalanine Nutrition 0.000 description 12
235000013305 food Nutrition 0.000 description 11
230000000694 effects Effects 0.000 description 10
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 10
229940024606 amino acid Drugs 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 9
125000003118 aryl group Chemical group 0.000 description 9
229960000310 isoleucine Drugs 0.000 description 9
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 9
239000008194 pharmaceutical composition Substances 0.000 description 9
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
230000006399 behavior Effects 0.000 description 8
229910052736 halogen Inorganic materials 0.000 description 8
150000002367 halogens Chemical class 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
239000004471 Glycine Substances 0.000 description 7
101800000989 Oxytocin Proteins 0.000 description 7
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 7
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 7
125000000753 cycloalkyl group Chemical group 0.000 description 7
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 7
229960001723 oxytocin Drugs 0.000 description 7
239000000902 placebo Substances 0.000 description 7
229940068196 placebo Drugs 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
239000000243 solution Substances 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
239000000556 agonist Substances 0.000 description 6
235000013930 proline Nutrition 0.000 description 6
238000012216 screening Methods 0.000 description 6
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
230000008859 change Effects 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
230000006872 improvement Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical compound NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
229910052731 fluorine Inorganic materials 0.000 description 4
235000013902 inosinic acid Nutrition 0.000 description 4
235000012054 meals Nutrition 0.000 description 4
150000002993 phenylalanine derivatives Chemical class 0.000 description 4
125000006413 ring segment Chemical group 0.000 description 4
FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical compound CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 description 3
208000008589 Obesity Diseases 0.000 description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
102000004279 Oxytocin receptors Human genes 0.000 description 3
108090000876 Oxytocin receptors Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
238000003556 assay Methods 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
201000010099 disease Diseases 0.000 description 3
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
125000005842 heteroatom Chemical group 0.000 description 3
229960002591 hydroxyproline Drugs 0.000 description 3
238000005259 measurement Methods 0.000 description 3
235000016709 nutrition Nutrition 0.000 description 3
235000020824 obesity Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
PEMUHKUIQHFMTH-QMMMGPOBSA-N (2s)-2-amino-3-(4-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-QMMMGPOBSA-N 0.000 description 2
WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
KQLGGQARRCMYGD-UHFFFAOYSA-N 2-(cyclobutylamino)acetic acid Chemical compound OC(=O)CNC1CCC1 KQLGGQARRCMYGD-UHFFFAOYSA-N 0.000 description 2
LRHRHAWNXCGABU-UHFFFAOYSA-N 2-(cyclopentylazaniumyl)acetate Chemical compound OC(=O)CNC1CCCC1 LRHRHAWNXCGABU-UHFFFAOYSA-N 0.000 description 2
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
208000028698 Cognitive impairment Diseases 0.000 description 2
NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010021118 Hypotonia Diseases 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
208000007379 Muscle Hypotonia Diseases 0.000 description 2
102000004136 Vasopressin Receptors Human genes 0.000 description 2
108090000643 Vasopressin Receptors Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
208000016361 genetic disease Diseases 0.000 description 2
150000002332 glycine derivatives Chemical class 0.000 description 2
150000002333 glycines Chemical class 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
150000002994 phenylalanines Chemical class 0.000 description 2
150000003147 proline derivatives Chemical group 0.000 description 2
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
FKVAWEVSZYLWIO-SSDOTTSWSA-N (2r)-2-azaniumyl-2-(furan-2-yl)propanoate Chemical compound [O-]C(=O)[C@@]([NH3+])(C)C1=CC=CO1 FKVAWEVSZYLWIO-SSDOTTSWSA-N 0.000 description 1
IWXYYBBSXLPWOR-BYPYZUCNSA-N (2s)-2-(1,3-thiazol-5-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CN=CS1 IWXYYBBSXLPWOR-BYPYZUCNSA-N 0.000 description 1
UWVASQFNBWGEJU-BYPYZUCNSA-N (2s)-2-(1h-imidazol-5-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CN=CN1 UWVASQFNBWGEJU-BYPYZUCNSA-N 0.000 description 1
IBQRCSSQJAGBBA-JTQLQIEISA-N (2s)-2-(2,2-dimethylhydrazinyl)-3-phenylpropanoic acid Chemical compound CN(C)N[C@H](C(O)=O)CC1=CC=CC=C1 IBQRCSSQJAGBBA-JTQLQIEISA-N 0.000 description 1
HKZCDMUOAAWVBO-YFKPBYRVSA-N (2s)-2-(furan-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC=1C=COC=1 HKZCDMUOAAWVBO-YFKPBYRVSA-N 0.000 description 1
CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 description 1
WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 description 1
SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 description 1
WRQSUCJAKAMYMQ-YFKPBYRVSA-N (2s)-2-(thiophen-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC=1C=CSC=1 WRQSUCJAKAMYMQ-YFKPBYRVSA-N 0.000 description 1
REBWUCRWJNKVLL-LURJTMIESA-N (2s)-2-amino-3-(1h-pyrrol-2-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CN1 REBWUCRWJNKVLL-LURJTMIESA-N 0.000 description 1
DQLHSFUMICQIMB-VIFPVBQESA-N (2s)-2-amino-3-(4-methylphenyl)propanoic acid Chemical compound CC1=CC=C(C[C@H](N)C(O)=O)C=C1 DQLHSFUMICQIMB-VIFPVBQESA-N 0.000 description 1
PHTSEYXRINISNN-JTQLQIEISA-N (2s)-2-amino-3-[4-(2-hydroxyethyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(CCO)C=C1 PHTSEYXRINISNN-JTQLQIEISA-N 0.000 description 1
OXNUZCWFCJRJSU-VIFPVBQESA-N (2s)-2-amino-3-[4-(hydroxymethyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(CO)C=C1 OXNUZCWFCJRJSU-VIFPVBQESA-N 0.000 description 1
RMYPEYHEPIZYDJ-JTQLQIEISA-N (2s)-2-azaniumyl-3-(4-ethoxyphenyl)propanoate Chemical compound CCOC1=CC=C(C[C@H](N)C(O)=O)C=C1 RMYPEYHEPIZYDJ-JTQLQIEISA-N 0.000 description 1
AWKDBHFQJATNBQ-JTQLQIEISA-N (2s)-2-azaniumyl-3-(4-ethylphenyl)propanoate Chemical compound CCC1=CC=C(C[C@H](N)C(O)=O)C=C1 AWKDBHFQJATNBQ-JTQLQIEISA-N 0.000 description 1
PPRFZPZRQYPCER-BKLSDQPFSA-N (2s)-4-azidopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(N=[N+]=[N-])CN1 PPRFZPZRQYPCER-BKLSDQPFSA-N 0.000 description 1
ZIWHMENIDGOELV-BKLSDQPFSA-N (2s)-4-fluoropyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(F)CN1 ZIWHMENIDGOELV-BKLSDQPFSA-N 0.000 description 1
RNXKXUOGQKYKTH-AKGZTFGVSA-N (2s)-4-methoxypyrrolidine-2-carboxylic acid Chemical compound COC1CN[C@H](C(O)=O)C1 RNXKXUOGQKYKTH-AKGZTFGVSA-N 0.000 description 1
OCQICQZUUHJWGZ-BYPYZUCNSA-N (4R)-2,2-dimethyl-1,3-thiazolidine-4-carboxylic acid Chemical compound CC1(C)N[C@H](C(O)=O)CS1 OCQICQZUUHJWGZ-BYPYZUCNSA-N 0.000 description 1
WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
OYNANFOWNSGDJL-UHFFFAOYSA-N 4-sulfanylpyrrolidin-1-ium-2-carboxylate Chemical compound OC(=O)C1CC(S)CN1 OYNANFOWNSGDJL-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010009137 Chronic sinusitis Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
206010011469 Crying Diseases 0.000 description 1
206010012559 Developmental delay Diseases 0.000 description 1
108090000331 Firefly luciferases Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000033334 Maternal uniparental disomy Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000030880 Nose disease Diseases 0.000 description 1
GEYBMYRBIABFTA-UHFFFAOYSA-N O-methyltyrosine Chemical compound COC1=CC=C(CC(N)C(O)=O)C=C1 GEYBMYRBIABFTA-UHFFFAOYSA-N 0.000 description 1
206010029897 Obsessive thoughts Diseases 0.000 description 1
206010058605 Poor sucking reflex Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
230000036528 appetite Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
208000029560 autism spectrum disease Diseases 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000027157 chronic rhinosinusitis Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
231100000867 compulsive behavior Toxicity 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
231100000020 developmental retardation Toxicity 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019138 food restriction Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
230000008140 language development Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
239000004531 microgranule Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000008111 motor development Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
230000008775 paternal effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
150000003148 prolines Chemical class 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Otolaryngology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Inorganic Chemistry (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CN202110278199.4A 2014-09-19 2015-09-14 治疗普拉德-威利综合征的方法 Pending CN112773765A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462052957P	2014-09-19	2014-09-19
US62/052,957		2014-09-19
CN201580049147.2A CN106714819A (zh)	2014-09-19	2015-09-14	治疗普拉德‑威利综合征的方法

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201580049147.2A Division CN106714819A (zh)	2014-09-19	2015-09-14	治疗普拉德‑威利综合征的方法

Publications (1)

Publication Number	Publication Date
CN112773765A true CN112773765A (zh)	2021-05-11

Family

ID=54238564

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN202110278199.4A Pending CN112773765A (zh)	2014-09-19	2015-09-14	治疗普拉德-威利综合征的方法
CN201580049147.2A Pending CN106714819A (zh)	2014-09-19	2015-09-14	治疗普拉德‑威利综合征的方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN201580049147.2A Pending CN106714819A (zh)	2014-09-19	2015-09-14	治疗普拉德‑威利综合征的方法

Country Status (16)

Country	Link
US (3)	US10441627B2 (2)
EP (2)	EP3193907B1 (2)
JP (3)	JP6599447B2 (2)
CN (2)	CN112773765A (2)
CA (1)	CA2957224A1 (2)
DK (1)	DK3666258T3 (2)
ES (2)	ES2970059T3 (2)
FI (1)	FI3666258T3 (2)
HR (1)	HRP20240166T1 (2)
HU (1)	HUE065829T2 (2)
LT (1)	LT3666258T (2)
PL (1)	PL3666258T3 (2)
PT (1)	PT3666258T (2)
RS (1)	RS65144B1 (2)
SI (1)	SI3666258T1 (2)
WO (1)	WO2016044131A1 (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2970059T3 (es)	2014-09-19	2024-05-24	Ferring Bv	Método de tratamiento del síndrome de Prader-Willi
US20190135859A1 (en)	2017-08-11	2019-05-09	Ferring B.V.	Method of manufacturing a pharmaceutical composition
BR112020001832A2 (pt)	2017-08-11	2020-07-28	Ferring B.V.	método de produção de uma composição farmacêuti-ca
US10736894B2 (en)	2018-02-15	2020-08-11	Ovid Therapeutics Inc.	Methods of treating developmental syndromes with PDE10A inhibitors
EP3852724A4 (en)	2018-09-20	2022-07-06	Levo Therapeutics, Inc.	CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
TW202031283A (zh) *	2018-09-20	2020-09-01	馬克Ｃ曼寧	穩定卡貝縮宮素鼻內製劑
CA3205469A1 (en) *	2020-12-18	2022-06-23	The General Hospital Corporation	Probiotics compositions and method of using the same to enhance growth and social function in children
ES3010259T3 (en)	2021-03-26	2025-04-01	Ot4B	Treatment of dysphagia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102656183A (zh) *	2009-09-21	2012-09-05	辉凌国际制药（瑞士）有限公司	催产素受体激动剂
CN103124554A (zh) *	2010-09-30	2013-05-29	辉凌公司	药物组合物
WO2014111356A1 (en) *	2013-01-17	2014-07-24	F. Hoffmann-La Roche Ag	Oxytocin receptor agonists for the treatment of cns diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7544662B2 (en)	1993-06-17	2009-06-09	Carle Development Foundation	Polypeptides useful for appetite suppression
US20070032410A1 (en)	2000-01-11	2007-02-08	Atossa Healthcare, Inc.	Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) *	2000-01-11	2005-05-17	Atossa Healthcare, Inc.	Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US9023793B2 (en)	2006-09-29	2015-05-05	Retrophin, Inc.	Intranasal carbetocin formulations and methods for the treatment of autism
CA2689476C (en) *	2007-06-07	2014-08-05	Nastech Pharmaceutical Company Inc.	Intranasal carbetocin formulations and methods for the treatment of autism
EP2187907A2 (en)	2007-09-11	2010-05-26	Mondobiotech Laboratories AG	Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
WO2009033820A2 (en)	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
KR20100057642A (ko)	2007-09-11	2010-05-31	몬도바이오테크 래보래토리즈 아게	치료제로서의 ｃｎｐ-２２ 단독 또는 피살라에민과 배합된 이의 용도
US20100184708A1 (en)	2007-09-11	2010-07-22	Dorian Bevec	Use of gly-pro-glu-oh (gpe) as a therapeutic agent
EP2260053B1 (en) *	2008-03-31	2014-05-14	Ferring BV	Oxytocin analogues
US8865746B2 (en)	2008-07-18	2014-10-21	Zafgen, Inc.	Methods of treating an overweight or obese subject
US20120108510A1 (en)	2010-05-20	2012-05-03	Emory University	Methods of improving behavioral therapies
EP2575853B1 (en)	2010-05-25	2016-08-24	INSERM - Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
WO2012149472A2 (en)	2011-04-27	2012-11-01	Ignite Institute For Individualized Health	Methods, compositions, and kits for treating and preventing neurological conditions
EP2935312B1 (en)	2012-12-21	2018-08-08	F.Hoffmann-La Roche Ag	Peptides as oxytocin agonists
AU2015270723A1 (en)	2014-06-03	2016-11-17	F. Hoffmann-La Roche Ag	Peptides as oxytocin agonists
CR20160562A (es)	2014-06-06	2017-01-06	Hoffmann La Roche	Péptidos como agonistas de la oxitocina
HRP20181916T1 (hr)	2014-08-07	2019-01-11	F. Hoffmann - La Roche Ag	Postupci pripreme oksitocinskih analoga
ES2970059T3 (es) *	2014-09-19	2024-05-24	Ferring Bv	Método de tratamiento del síndrome de Prader-Willi

2015
- 2015-09-14 ES ES19216650T patent/ES2970059T3/es active Active
- 2015-09-14 EP EP15772107.7A patent/EP3193907B1/en active Active
- 2015-09-14 CN CN202110278199.4A patent/CN112773765A/zh active Pending
- 2015-09-14 PT PT192166502T patent/PT3666258T/pt unknown
- 2015-09-14 EP EP19216650.2A patent/EP3666258B1/en active Active
- 2015-09-14 LT LTEP19216650.2T patent/LT3666258T/lt unknown
- 2015-09-14 CA CA2957224A patent/CA2957224A1/en active Pending
- 2015-09-14 RS RS20240134A patent/RS65144B1/sr unknown
- 2015-09-14 CN CN201580049147.2A patent/CN106714819A/zh active Pending
- 2015-09-14 SI SI201531990T patent/SI3666258T1/sl unknown
- 2015-09-14 DK DK19216650.2T patent/DK3666258T3/da active
- 2015-09-14 US US15/510,781 patent/US10441627B2/en active Active
- 2015-09-14 HR HRP20240166TT patent/HRP20240166T1/hr unknown
- 2015-09-14 JP JP2017515228A patent/JP6599447B2/ja active Active
- 2015-09-14 WO PCT/US2015/049911 patent/WO2016044131A1/en not_active Ceased
- 2015-09-14 PL PL19216650.2T patent/PL3666258T3/pl unknown
- 2015-09-14 HU HUE19216650A patent/HUE065829T2/hu unknown
- 2015-09-14 ES ES15772107T patent/ES2775425T3/es active Active
- 2015-09-14 FI FIEP19216650.2T patent/FI3666258T3/fi active
2019
- 2019-10-02 JP JP2019181930A patent/JP6921154B2/ja active Active
- 2019-10-03 US US16/592,632 patent/US20200129584A1/en not_active Abandoned
2021
- 2021-03-15 JP JP2021041334A patent/JP2021098745A/ja active Pending
2022
- 2022-11-18 US US18/057,065 patent/US20240082344A1/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102656183A (zh) *	2009-09-21	2012-09-05	辉凌国际制药（瑞士）有限公司	催产素受体激动剂
CN103124554A (zh) *	2010-09-30	2013-05-29	辉凌公司	药物组合物
WO2014111356A1 (en) *	2013-01-17	2014-07-24	F. Hoffmann-La Roche Ag	Oxytocin receptor agonists for the treatment of cns diseases

Also Published As

Publication number	Publication date
RS65144B1 (sr)	2024-02-29
DK3666258T3 (da)	2024-02-05
WO2016044131A1 (en)	2016-03-24
CA2957224A1 (en)	2016-03-24
US10441627B2 (en)	2019-10-15
US20200129584A1 (en)	2020-04-30
JP6921154B2 (ja)	2021-08-18
JP2017532316A (ja)	2017-11-02
SI3666258T1 (sl)	2024-04-30
JP6599447B2 (ja)	2019-10-30
US20170326200A1 (en)	2017-11-16
HUE065829T2 (hu)	2024-06-28
ES2775425T3 (es)	2020-07-27
HRP20240166T1 (hr)	2024-04-26
US20240082344A1 (en)	2024-03-14
EP3193907A1 (en)	2017-07-26
JP2020019790A (ja)	2020-02-06
PT3666258T (pt)	2024-02-01
LT3666258T (lt)	2024-01-10
FI3666258T3 (fi)	2024-02-09
JP2021098745A (ja)	2021-07-01
EP3666258B1 (en)	2023-11-15
EP3666258A1 (en)	2020-06-17
ES2970059T3 (es)	2024-05-24
CN106714819A (zh)	2017-05-24
EP3193907B1 (en)	2020-01-01
PL3666258T3 (pl)	2024-04-08

Legal Events

Date	Code	Title
2021-05-11	PB01	Publication
2021-05-11	PB01	Publication
2021-05-28	SE01	Entry into force of request for substantive examination
2021-05-28	SE01	Entry into force of request for substantive examination

Publication	Publication Date	Title
JP6921154B2 (ja)	2021-08-18	プラダー・ウィリー症候群を治療する方法
AU2013205648B2 (en)	2015-02-05	Combination treatment
US10092564B2 (en)	2018-10-09	Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
US20200276136A1 (en)	2020-09-03	Method of treating selected patient population experiencing dravet syndrome
CN114929209A (zh)	2022-08-19	肌萎缩侧索硬化的治疗
US20190247333A1 (en)	2019-08-15	Method of reduction in convulsive seizure frequency
US20220133652A1 (en)	2022-05-05	A formulation for improving seizure control
WO2019067413A1 (en)	2019-04-04	USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20220151960A1 (en)	2022-05-19	Treatment of symptoms associated with female gastroparesis
MX2014002125A (es)	2014-10-17	Tratamiento de sintomas asociados a gastroparesia femenina.
IL303006A (en)	2023-07-01	Use of pyridofidine and analogues for the treatment of Rett syndrome
PH12015500915B1 (en)	2015-06-29	Uses of bremelanotide in therapy for female sexual dysfunction
WO2025255116A1 (en)	2025-12-11	Methods of treatment for opioid-induced ventilatory depression and muscle rigidity
US8680145B1 (en)	2014-03-25	Compositions and methods for treatment of fear of medical procedures
HK40081935A (en)	2023-06-02	Treatment of amyotrophic lateral sclerosis
JP2006117569A (ja)	2006-05-11	ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬